Atlas Trials

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Clinical trial NCT02452047 · COMPLETED

Trial details

NCT number
NCT02452047
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Bacterial Infections
Start date
2015-08-21
Primary completion
2017-09-18
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.